Pegylated interferon alpha2a
Phase 3Small molecule
Pegylated interferon alpha2a is one of 142 small molecule programs targeting Liver Transplant. It is currently in Phase 3.
4
Indications
8
Total Trials
1
Active Trials
141
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
624 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Pegylated interferon alpha2a
EEnyo Pharma
Phase 3
PEG-Intron
Merck & Co.Preclinical
Sovaldi
GileadPreclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Incivek
Vertex PharmaceuticalsPreclinical
Intron a
SanofiPreclinical
Roferon-a
RochePreclinical
Medrol
PfizerPreclinical
SOF/VEL
GileadPreclinical
Keyhole-Limpet Hemocyanin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis3 trials
Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158496·100 enrolled
Hepatitis C1 trial
Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158522·31 enrolled
Myelofibrosis1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EEnyo Pharma